The effective combination therapies with irinotecan for colorectal cancer
Colorectal cancer is the third most common type of cancer worldwide and has become one of the major human disease burdens. In clinical practice, the treatment of colorectal cancer has been closely related to the use of irinotecan. Irinotecan combines with many other anticancer drugs and has a broade...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1356708/full |
| _version_ | 1827357823599640576 |
|---|---|
| author | Yun Chai Jing-Li Liu Shuo Zhang Shuo Zhang Na Li Ding-Qiao Xu Wen-Juan Liu Rui-Jia Fu Yu-Ping Tang |
| author_facet | Yun Chai Jing-Li Liu Shuo Zhang Shuo Zhang Na Li Ding-Qiao Xu Wen-Juan Liu Rui-Jia Fu Yu-Ping Tang |
| author_sort | Yun Chai |
| collection | DOAJ |
| description | Colorectal cancer is the third most common type of cancer worldwide and has become one of the major human disease burdens. In clinical practice, the treatment of colorectal cancer has been closely related to the use of irinotecan. Irinotecan combines with many other anticancer drugs and has a broader range of drug combinations. Combination therapy is one of the most important means of improving anti-tumor efficacy and overcoming drug resistance. Reasonable combination therapy can lead to better patient treatment options, and inappropriate combination therapy will increase patient risk. For the colorectal therapeutic field, the significance of combination therapy is to improve the efficacy, reduce the adverse effects, and improve the ease of treatment. Therefore, we explored the clinical advantages of its combination therapy based on mechanism or metabolism and reviewed the rationale basis and its limitations in conducting exploratory clinical trials on irinotecan combination therapy, including the results of clinical trials on the combination potentiation of cytotoxic drugs, targeted agents, and herbal medicine. We hope that these can evoke more efforts to conduct irinotecan in the laboratory for further studies and evaluations, as well as the possibility of more in-depth development in future clinical trials. |
| first_indexed | 2024-03-08T05:53:35Z |
| format | Article |
| id | doaj.art-5d1c8383fc5848d288543f24733b0f22 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T05:53:35Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-5d1c8383fc5848d288543f24733b0f222024-02-05T04:59:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-02-011510.3389/fphar.2024.13567081356708The effective combination therapies with irinotecan for colorectal cancerYun Chai0Jing-Li Liu1Shuo Zhang2Shuo Zhang3Na Li4Ding-Qiao Xu5Wen-Juan Liu6Rui-Jia Fu7Yu-Ping Tang8Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaKey Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, ChinaColorectal cancer is the third most common type of cancer worldwide and has become one of the major human disease burdens. In clinical practice, the treatment of colorectal cancer has been closely related to the use of irinotecan. Irinotecan combines with many other anticancer drugs and has a broader range of drug combinations. Combination therapy is one of the most important means of improving anti-tumor efficacy and overcoming drug resistance. Reasonable combination therapy can lead to better patient treatment options, and inappropriate combination therapy will increase patient risk. For the colorectal therapeutic field, the significance of combination therapy is to improve the efficacy, reduce the adverse effects, and improve the ease of treatment. Therefore, we explored the clinical advantages of its combination therapy based on mechanism or metabolism and reviewed the rationale basis and its limitations in conducting exploratory clinical trials on irinotecan combination therapy, including the results of clinical trials on the combination potentiation of cytotoxic drugs, targeted agents, and herbal medicine. We hope that these can evoke more efforts to conduct irinotecan in the laboratory for further studies and evaluations, as well as the possibility of more in-depth development in future clinical trials.https://www.frontiersin.org/articles/10.3389/fphar.2024.1356708/fullcolorectal canceririnotecancancer therapydrug combinationstargeted drugherbal medicine |
| spellingShingle | Yun Chai Jing-Li Liu Shuo Zhang Shuo Zhang Na Li Ding-Qiao Xu Wen-Juan Liu Rui-Jia Fu Yu-Ping Tang The effective combination therapies with irinotecan for colorectal cancer Frontiers in Pharmacology colorectal cancer irinotecan cancer therapy drug combinations targeted drug herbal medicine |
| title | The effective combination therapies with irinotecan for colorectal cancer |
| title_full | The effective combination therapies with irinotecan for colorectal cancer |
| title_fullStr | The effective combination therapies with irinotecan for colorectal cancer |
| title_full_unstemmed | The effective combination therapies with irinotecan for colorectal cancer |
| title_short | The effective combination therapies with irinotecan for colorectal cancer |
| title_sort | effective combination therapies with irinotecan for colorectal cancer |
| topic | colorectal cancer irinotecan cancer therapy drug combinations targeted drug herbal medicine |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1356708/full |
| work_keys_str_mv | AT yunchai theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT jingliliu theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT shuozhang theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT shuozhang theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT nali theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT dingqiaoxu theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT wenjuanliu theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT ruijiafu theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT yupingtang theeffectivecombinationtherapieswithirinotecanforcolorectalcancer AT yunchai effectivecombinationtherapieswithirinotecanforcolorectalcancer AT jingliliu effectivecombinationtherapieswithirinotecanforcolorectalcancer AT shuozhang effectivecombinationtherapieswithirinotecanforcolorectalcancer AT shuozhang effectivecombinationtherapieswithirinotecanforcolorectalcancer AT nali effectivecombinationtherapieswithirinotecanforcolorectalcancer AT dingqiaoxu effectivecombinationtherapieswithirinotecanforcolorectalcancer AT wenjuanliu effectivecombinationtherapieswithirinotecanforcolorectalcancer AT ruijiafu effectivecombinationtherapieswithirinotecanforcolorectalcancer AT yupingtang effectivecombinationtherapieswithirinotecanforcolorectalcancer |